Synaptogenix and cleveland clinic to submit investigational new drug (ind) application to fda for clinical trial of bryostatin-1 in multiple sclerosis

Study will evaluate drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in ms patients new york , july 19, 2023 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("synaptogenix" or the "company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it entered into an agreement with cleveland clinic to conduct a phase 1 trial of bryostatin-1 in multiple sclerosis (ms). cleveland clinic will manage the clinical trial's implementation, including an investigational new drug (ind) submission to the us food and drug administration and patient enrollment.
SNPX Ratings Summary
SNPX Quant Ranking